Tick-Transmitted Diseases in Dogs: Comprehensive Clinical Guide
Introduction
Tick-transmitted diseases represent a significant and growing burden in canine medicine worldwide. The geographic expansion of tick vectors, driven by climate change and habitat alteration, has increased the exposure of domestic dogs to a diverse array of bacterial, protozoal, and rickettsial pathogens [1]. These pathogens, transmitted during the blood-feeding process of ixodid ticks, can cause acute, chronic, and sometimes fatal illnesses. This comprehensive clinical guide provides a detailed review of the major tick-transmitted diseases affecting dogs, with a focus on epidemiology, pathophysiology, clinical presentation, diagnostic modalities, therapeutic protocols, and preventive strategies. The term "dog tick transmitted diseases" encompasses a spectrum of infections that require a high index of clinical suspicion and a systematic diagnostic approach [2].
Major Tick-Transmitted Pathogens in Dogs
The primary pathogens responsible for tick-transmitted diseases in dogs can be categorized into three groups: bacteria (including rickettsiae), protozoa, and, less commonly, viruses. The most clinically relevant organisms are discussed below.
Bacterial Pathogens
Ehrlichia canis is the causative agent of canine monocytic ehrlichiosis. This obligate intracellular gram-negative bacterium infects monocytes and macrophages, leading to a multisystemic disease [3]. The primary vector is the brown dog tick, Rhipicephalus sanguineus. Transmission occurs after the tick has fed for 24 to 48 hours, allowing the bacteria to replicate in salivary glands and be inoculated into the host [4].
Anaplasma phagocytophilum and Anaplasma platys are two distinct species causing disease in dogs. A. phagocytophilum infects neutrophils and is transmitted by Ixodes species ticks, resulting in canine granulocytic anaplasmosis [5]. A. platys is a thrombocytotropic organism that infects platelets, causing infectious cyclic thrombocytopenia, and is also transmitted by R. sanguineus [6].
Borrelia burgdorferi sensu lato is the spirochete responsible for canine Lyme disease (borreliosis). Transmitted primarily by Ixodes scapularis and Ixodes pacificus in North America, the spirochete migrates from the tick midgut to the salivary glands during feeding, a process that typically requires 36 to 48 hours of attachment [7].
Protozoal Pathogens
Babesia canis and Babesia gibsoni are intraerythrocytic protozoan parasites that cause canine babesiosis. B. canis is a large piroplasm transmitted by Dermacentor and Rhipicephalus ticks, while B. gibsoni is a small piroplasm with a more complex epidemiology, including transmission via Haemaphysalis ticks and direct dog-to-dog transmission through bite wounds [8].
Hepatozoon canis is a unique tick-transmitted protozoan. Unlike other tick-borne pathogens, transmission occurs not through the tick's saliva but through ingestion of the tick vector, R. sanguineus, by the dog. The parasite then undergoes merogony in various tissues, including the spleen and bone marrow [9].
Epidemiology and Vector Ecology
The epidemiology of dog tick transmitted diseases is intrinsically linked to the ecology of the tick vectors. Rhipicephalus sanguineus, the brown dog tick, is a three-host tick that can complete its entire life cycle indoors, making it a particularly effective vector in kennel environments and domestic settings [10]. This tick is the primary vector for E. canis, A. platys, and H. canis.
Ixodes species ticks, including I. scapularis (the black-legged tick) and I. pacificus (the western black-legged tick), are the primary vectors for A. phagocytophilum and B. burgdorferi. These ticks require high humidity and are typically found in wooded or grassy areas [11]. The prevalence of these pathogens in tick populations varies geographically and seasonally, with peak transmission occurring during the nymphal and adult tick activity periods in spring and fall [12].
Dermacentor variabilis (the American dog tick) and Dermacentor andersoni (the Rocky Mountain wood tick) are vectors for B. canis and Francisella tularensis (tularemia, a less common canine pathogen) [13]. The geographic distribution of these ticks overlaps with that of the pathogens they transmit, creating endemic regions for specific diseases.
Clinical Signs and Pathophysiology
Canine Monocytic Ehrlichiosis (Ehrlichia canis)
The clinical course of E. canis infection is classically divided into three phases: acute, subclinical, and chronic [14]. The acute phase, occurring 1 to 3 weeks after tick inoculation, is characterized by fever, lethargy, anorexia, lymphadenomegaly, and splenomegaly. Thrombocytopenia is a hallmark laboratory finding, resulting from immune-mediated destruction and platelet sequestration [15]. The subclinical phase can persist for months to years, during which the dog appears clinically normal but remains persistently infected. The chronic phase is the most severe, manifesting as pancytopenia, epistaxis, uveitis, polyarthritis, and glomerulonephritis due to immune complex deposition [16].
Canine Granulocytic Anaplasmosis (Anaplasma phagocytophilum)
Infection with A. phagocytophilum typically presents with an acute onset of fever, lethargy, and inappetence, often accompanied by lameness due to polyarthritis [17]. The pathophysiology involves the infection of neutrophils, leading to impaired neutrophil function and a systemic inflammatory response. Thrombocytopenia is common, though less severe than in ehrlichiosis. Vomiting, diarrhea, and neurologic signs (ataxia, seizures) are reported in a subset of cases [18].
Canine Anaplasmosis (Anaplasma platys)
A. platys infection is characterized by cyclical thrombocytopenia, with platelet counts dropping every 10 to 14 days as the parasite undergoes its reproductive cycle within platelets [19]. Clinical signs are often mild or absent, but can include fever, lethargy, petechiation, and epistaxis during periods of severe thrombocytopenia. Co-infections with E. canis are common and can exacerbate clinical severity [20].
Canine Lyme Disease (Borrelia burgdorferi)
The clinical presentation of canine Lyme disease is variable. The most common manifestation is acute-onset lameness due to immune-mediated polyarthritis, often shifting between limbs [21]. Fever, lethargy, and lymphadenopathy are frequently present. A pathognomonic skin lesion, erythema migrans, is rarely observed in dogs due to their dense hair coat. A significant proportion of infected dogs remain asymptomatic. The most serious complication is Lyme nephropathy, an immune-complex glomerulonephritis that can progress to renal failure and carries a poor prognosis [22].
Canine Babesiosis (Babesia canis and Babesia gibsoni)
Babesiosis presents as a hemolytic disease. The acute form is characterized by fever, anemia, icterus, hemoglobinuria, and splenomegaly [23]. B. canis infection tends to cause more severe hemolytic anemia, while B. gibsoni infection can result in a chronic, regenerative anemia that is more difficult to diagnose. The pathophysiology involves direct erythrocyte lysis by the replicating parasite and immune-mediated destruction of infected and uninfected red blood cells. Severe cases can lead to disseminated intravascular coagulation and multi-organ failure [24].
Canine Hepatozoonosis (Hepatozoon canis)
Hepatozoonosis presents with a distinct clinical picture. Affected dogs exhibit fever, lethargy, muscle atrophy, and a characteristic stiff gait or hyperesthesia due to myositis and periostitis [25]. The pathophysiology involves the formation of meronts in skeletal and cardiac muscle, leading to a severe pyogranulomatous inflammatory response. Leukocytosis, particularly neutrophilia, is a prominent laboratory finding [26].
Diagnostic Approaches
The diagnosis of dog tick transmitted diseases relies on a combination of signalment, history, physical examination findings, and laboratory testing. A systematic diagnostic algorithm is essential.
Hematology and Biochemistry
Complete blood count (CBC) and serum biochemistry are critical initial steps. Thrombocytopenia is a common thread across many tick-borne diseases, particularly ehrlichiosis and anaplasmosis [27]. Anemia, leukopenia, or leukocytosis may be present. Serum biochemistry may reveal hyperglobulinemia (especially in chronic ehrlichiosis), azotemia (in Lyme nephropathy), and elevated liver enzymes.
Cytology and Microscopy
Examination of blood smears can provide a rapid, point-of-care diagnosis in some cases. Intracytoplasmic inclusions (morulae) of E. canis may be visible in monocytes, and morulae of A. phagocytophilum may be seen in neutrophils [28]. Babesia organisms can be identified within erythrocytes as pear-shaped or ring-shaped piroplasms. However, sensitivity is low, especially in chronic or low-parasitemia infections [29].
Serology
Serologic testing for antibodies is a cornerstone of diagnosis. Indirect immunofluorescence assays (IFA) and enzyme-linked immunosorbent assays (ELISA) are widely used. Detection of antibodies to E. canis, A. phagocytophilum, A. platys, and B. burgdorferi is common [30]. For Lyme disease, detection of antibodies to the C6 peptide of B. burgdorferi is highly specific and can differentiate between natural infection and vaccine-induced antibodies [31]. A four-fold rise in antibody titer between acute and convalescent samples is considered diagnostic for active infection.
Molecular Diagnostics
Polymerase chain reaction (PCR) assays offer high sensitivity and specificity for detecting pathogen DNA in blood or tissue samples. PCR is particularly useful for detecting Babesia species, E. canis in the acute phase, and for confirming active infection in seropositive dogs [32]. Quantitative PCR (qPCR) can provide information on pathogen load, which may correlate with disease severity.
Diagnostic Algorithm
The following Mermaid diagram outlines a recommended diagnostic workflow for a dog presenting with suspected tick-transmitted disease.
flowchart TD
A[Clinical Suspicion: Fever, Lethargy, Lameness, Thrombocytopenia], > B{Point-of-Care SNAP Test}
B, >|Positive for E. canis, A. phagocytophilum, or B. burgdorferi| C[Confirmatory PCR or IFA]
B, >|Negative| D[Blood Smear for Babesia / Morulae]
D, >|Positive| E[Species-specific PCR]
D, >|Negative| F[Advanced Serology: IFA Panel]
F, >|Positive| G[PCR for Confirmation]
F, >|Negative| H[Consider Hepatozoonosis: Muscle Biopsy / PCR]
C, > I[Initiate Targeted Therapy]
E, > I
G, > I
H, > I
Treatment Protocols
Therapeutic strategies are pathogen-specific and must be tailored to the clinical severity and chronicity of the infection.
Ehrlichiosis and Anaplasmosis
The treatment of choice for both E. canis and A. phagocytophilum infection is doxycycline (10 mg/kg orally every 24 hours for 28 days) [33]. Clinical improvement is typically observed within 24 to 48 hours. For severe or chronic ehrlichiosis, supportive care including fluid therapy, blood transfusions for severe anemia or thrombocytopenia, and immunosuppressive doses of corticosteroids (e.g., prednisone 1-2 mg/kg/day) may be necessary to control immune-mediated complications [34]. Imidocarb dipropionate is an alternative for E. canis but is less effective than doxycycline.
Lyme Disease
Doxycycline is also the first-line therapy for canine Lyme disease (10 mg/kg orally every 24 hours for 30 days) [35]. Amoxicillin or cefovecin may be used as alternatives. Clinical signs of arthritis typically resolve rapidly. For dogs with Lyme nephropathy, aggressive supportive care including fluid therapy, angiotensin-converting enzyme inhibitors, and immunosuppressive therapy is required, though the prognosis remains guarded [36].
Babesiosis
Treatment for babesiosis depends on the species. For B. canis, imidocarb dipropionate (5-6.6 mg/kg intramuscularly or subcutaneously, repeated once after 14 days) is the drug of choice [37]. For B. gibsoni, a combination of atovaquone (13.3 mg/kg orally every 8 hours for 10 days) and azithromycin (10 mg/kg orally every 24 hours for 10 days) has shown superior efficacy [38]. Supportive care including fluid therapy and blood transfusions is critical in severe cases.
Hepatozoonosis
Treatment of hepatozoonosis is challenging and often requires a combination of therapies. A protocol using toltrazuril (5-10 mg/kg orally every 24 hours for 5 days) combined with doxycycline (10 mg/kg orally every 24 hours for 14 days) has been described [39]. Imidocarb dipropionate may also be used. Long-term management is often necessary due to the persistence of tissue stages.
Prevention and Control
Prevention of dog tick transmitted diseases relies on effective tick control and, where available, vaccination.
Tick Control
Year-round use of acaricidal products is the cornerstone of prevention. Topical spot-on formulations containing fipronil, imidacloprid, or permethrin, as well as oral isoxazoline compounds (e.g., afoxolaner, fluralaner, sarolaner), provide highly effective and sustained tick-killing activity [40]. Environmental management, including keeping grass short and removing leaf litter, reduces tick habitat. Regular tick checks and prompt removal of attached ticks are also important.
Vaccination
Vaccines are available for canine Lyme disease. These bacterin-based vaccines target outer surface proteins of B. burgdorferi and are effective at reducing the risk of infection and clinical disease [41]. Vaccination is recommended for dogs residing in or traveling to endemic areas. No commercially available vaccines exist for ehrlichiosis, anaplasmosis, babesiosis, or hepatozoonosis.
Conclusion
Tick-transmitted diseases in dogs represent a complex and evolving clinical challenge. A thorough understanding of the epidemiology, pathophysiology, and clinical presentation of each major pathogen is essential for accurate diagnosis and effective management. The diagnostic approach should integrate serologic and molecular methods to confirm infection and guide therapy. Prevention through rigorous tick control and, where appropriate, vaccination remains the most effective strategy for reducing the burden of these diseases. Clinicians must remain vigilant for emerging pathogens and changing geographic distributions of established vectors.
References
[1] Shaw SE, Day MJ, Birtles RJ, Breitschwerdt EB. Tick-borne infectious diseases of dogs. Trends Parasitol. 2001;17(2):74-80.
[2] Little SE. Changing paradigms in understanding the transmission of tick-borne diseases in dogs. Vet Clin North Am Small Anim Pract. 2010;40(6):1121-1134.
[3] Harrus S, Waner T. Diagnosis of canine monocytotropic ehrlichiosis (Ehrlichia canis): an overview. Vet J. 2011;187(3):292-296.
[4] Neer TM, Breitschwerdt EB, Greene RT, Lappin MR. Consensus statement on ehrlichial disease of small animals from the infectious disease study group of the ACVIM. J Vet Intern Med. 2002;16(3):309-315.
[5] Carrade DD, Foley JE, Borjesson DL, Sykes JE. Canine granulocytic anaplasmosis: a review. J Vet Intern Med. 2009;23(6):1129-1141.
[6] Harvey JW, Simpson CF, Gaskin JM. Cyclic thrombocytopenia induced by a Rickettsia-like agent in dogs. J Infect Dis. 1978;137(2):182-188.
[7] Littman MP, Gerber B, Goldstein RE, Labato MA, Lappin MR, Moore GE. ACVIM consensus update on Lyme borreliosis in dogs and cats. J Vet Intern Med. 2018;32(3):887-903.
[8] Irwin PJ. Canine babesiosis: from molecular taxonomy to control. Parasit Vectors. 2009;2(Suppl 1):S4.
[9] Baneth G. Hepatozoon canis infection. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier Saunders; 2012:750-757.
[10] Dantas-Torres F. Biology and ecology of the brown dog tick, Rhipicephalus sanguineus. Parasit Vectors. 2010;3:26.
[11] Ogden NH, Lindsay LR, Hanincová K, et al. Role of migratory birds in introduction and range expansion of Ixodes scapularis ticks and of Borrelia burgdorferi and Anaplasma phagocytophilum in Canada. Appl Environ Microbiol. 2008;74(6):1780-1790.
[12] Eisen RJ, Eisen L, Beard CB. County-scale distribution of Ixodes scapularis and Ixodes pacificus (Acari: Ixodidae) in the continental United States. J Med Entomol. 2016;53(2):349-386.
[13] Yabsley MJ. Natural history of Ehrlichia chaffeensis: vertebrate hosts and tick vectors. Vector Borne Zoonotic Dis. 2010;10(4):377-386.
[14] Harrus S, Waner T, Bark H. Canine monocytic ehrlichiosis: an update. Compend Contin Educ Pract Vet. 1997;19(4):431-444.
[15] Waner T, Harrus S, Weiss DJ, Bark H, Keysary A. Demonstration of serum antiplatelet antibodies in experimental acute canine ehrlichiosis. Vet Immunol Immunopathol. 1995;48(1-2):177-182.
[16] Codner EC, Roberts RE, Ainsworth AG. Atypical findings in 16 cases of canine ehrlichiosis. J Am Vet Med Assoc. 1985;186(2):166-169.
[17] Greig B, Asanovich KM, Armstrong PJ, Dumler JS. Geographic, clinical, serologic, and molecular evidence of granulocytic ehrlichiosis, a likely zoonotic disease, in Minnesota and Wisconsin dogs. J Clin Microbiol. 1996;34(1):44-48.
[18] Kohn B, Galke D, Beelitz P, Pfister K. Clinical features of canine granulocytic anaplasmosis in 18 naturally infected dogs. J Vet Intern Med. 2008;22(6):1289-1295.
[19] Baker DC, Simpson JL, Gaunt SD, Corstvet RE. Acute Ehrlichia platys infection in the dog. Vet Pathol. 1987;24(5):449-453.
[20] Gaunt SD, Baker DC, Babin SS. Platelet-associated immunoglobulin in dogs with Ehrlichia platys infection. Am J Vet Res. 1990;51(8):1231-1235.
[21] Levy SA, Magnarelli LA. Relationship between development of antibodies to Borrelia burgdorferi in dogs and the subsequent development of limb/joint borreliosis. J Am Vet Med Assoc. 1992;200(3):344-347.
[22] Dambach DM, Smith CA, Lewis RM, Van Winkle TJ. Morphologic, immunohistochemical, and ultrastructural characterization of a distinctive renal lesion in dogs putatively associated with Borrelia burgdorferi infection: 49 cases (1987-1992). Vet Pathol. 1997;34(2):85-96.
[23] Böhm M, Leisewitz AL, Thompson PN, Schoeman JP. Capillary and venous Babesia canis parasitaemias and their association with outcome of infection. Vet Parasitol. 2006;141(1-2):80-86.
[24] Jacobson LS. The South African form of severe and complicated canine babesiosis: clinical advances 1994-2004. Vet Parasitol. 2006;138(1-2):126-139.
[25] Baneth G, Weigler B. Retrospective case-control study of hepatozoonosis in dogs in Israel. J Vet Intern Med. 1997;11(6):365-370.
[26] Baneth G, Samish M, Shkap V. Life cycle of Hepatozoon canis (Apicomplexa: Adeleorina: Hepatozoidae) in the tick Rhipicephalus sanguineus and domestic dog (Canis familiaris). J Parasitol. 2007;93(2):283-299.
[27] Kuehn NF, Gaunt SD. Clinical and hematologic findings in canine ehrlichiosis. J Am Vet Med Assoc. 1985;186(4):355-358.
[28] Mylonakis ME, Koutinas AF, Breitschwerdt EB, et al. Chronic canine ehrlichiosis (Ehrlichia canis): a retrospective study of 19 natural cases. J Am Anim Hosp Assoc. 2004;40(3):174-184.
[29] Birkenheuer AJ, Levy MG, Breitschwerdt EB. Development and evaluation of a seminested PCR for detection and differentiation of Babesia gibsoni (Asian genotype) and B. canis DNA in canine blood samples. J Clin Microbiol. 2003;41(9):4172-4177.
[30] O'Connor TP, Esty KJ, MacHenry P, et al. Performance evaluation of Ehrlichia canis and Borrelia burgdorferi peptide-based ELISA in experimentally infected dogs. J Vet Diagn Invest. 2004;16(5):412-418.
[31] Liang FT, Jacobson RH, Straubinger RK, Grooters A, Philipp MT. Characterization of a Borrelia burgdorferi VlsE invariable region useful in canine Lyme disease serodiagnosis by enzyme-linked immunosorbent assay. J Clin Microbiol. 2000;38(11):4160-4166.
[32] Breitschwerdt EB, Hegarty BC, Hancock SI. Sequential evaluation of dogs naturally infected with Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia equi, Ehrlichia ewingii, or Bartonella vinsonii. J Clin Microbiol. 1998;36(9):2645-2651.
[33] Breitschwerdt EB. The role of the tetracyclines in the therapy of canine infectious diseases. J Am Vet Med Assoc. 1990;196(6):919-924.
[34] Harrus S, Waner T, Aizenberg I, Foley JE, Poland AM, Bark H. Amplification of ehrlichial DNA from dogs 34 months after infection with Ehrlichia canis. J Clin Microbiol. 1998;36(1):73-76.
[35] Straubinger RK, Straubinger AF, Summers BA, Jacobson RH, Erb HN. Borrelia burgdorferi induces the production and release of proinflammatory cytokines in canine synovial explant cultures. Infect Immun. 1998;66(1):247-252.
[36] Goldstein RE, Cordner AP, Sandler JL, Bellohusen BA, Erb HN. Microalbuminuria and comparison of serologic testing for exposure to Borrelia burgdorferi in nonclinical Labrador and Golden Retrievers. J Vet Diagn Invest. 2007;19(3):294-297.
[37] Vercammen F, De Deken R, Maes L. Clinical and serological observations on experimental infection with Babesia canis and its treatment with imidocarb dipropionate. Vet Parasitol. 1996;65(1-2):23-29.
[38] Birkenheuer AJ, Levy MG, Breitschwerdt EB. Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesia gibsoni (Asian genotype) infections in dogs. J Vet Intern Med. 2004;18(4):494-498.
[39] Baneth G, Shkap V. Monozoic cysts of Hepatozoon canis. J Parasitol. 2003;89(2):379-381.
[40] Blagburn BL, Dryden MW. Biology, treatment, and control of flea and tick infestations. Vet Clin North Am Small Anim Pract. 2009;39(6):1173-1200.
[41] Topfer KH, Straubinger RK. Characterization of the humoral immune response in dogs after vaccination with a commercial Lyme disease vaccine. Vet Immunol Immunopathol. 2007;118(1-2):55-65. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.